Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wobe-Mugos is a combination drug composed of **proteolytic enzymes**: papain, trypsin, and chymotrypsin. Its mechanism of action centers on the enzymatic breakdown of proteins, reducing inflammation, supporting wound healing, and aiding digestive processes. The drug is used clinically for managing joint pain, wound cleansing, digestive disorders, soreness, ulcers, and adjuvant support during chemotherapy and radiotherapy, with some evidence suggesting it may reduce chemotherapy-related toxicities such as leucopenia, nausea, and sensory neuropathy[1][3][4][5][7]. It is also studied for ameliorating early side effects (such as oral mucositis) of radiotherapy, although clinical efficacy in this setting is debated[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wobe-Mugos.